Search research articles
Contact Us
Filters
Showing results (131-140 of 238) with videos related to
Page
of 24
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 14, 2012
Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer
A T Shaw, A M Varghese, B J Solomon, et al.
Nature Medicine
|
November 11, 2014
Anchored multiplex PCR for targeted next-generation sequencing
Zongli Zheng, Matthew Liebers, Boryana Zhelyazkova, et al.
Cancer Research
|
March 29, 2014
Failure to induce apoptosis via BCL-2 family proteins underlies lack of efficacy of combined MEK and PI3K inhibitors for KRAS-mutant lung cancers
Aaron N Hata, Alan Yeo, Anthony C Faber, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
August 29, 2016
Programmed Cell Death Ligand 1 Expression in Resected Lung Adenocarcinomas: Association with Immune Microenvironment
Tiffany G Huynh, Vicente Morales-Oyarvide, Meghan J Campo, et al.
Cancer Cell
|
December 30, 2014
Measurement of PIP3 levels reveals an unexpected role for p110β in early adaptive responses to p110α-specific inhibitors in luminal breast cancer
Carlotta Costa, Hiromichi Ebi, Miriam Martini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 1, 2015
Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib
Justin F Gainor, Daniel S W Tan, Tomasso De Pas, et al.
Oncogene
|
August 8, 2017
Synergistic activity and heterogeneous acquired resistance of combined MDM2 and MEK inhibition in KRAS mutant cancers
A N Hata, S Rowley, H L Archibald, et al.
Cancer Research
|
March 11, 2010
An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation
Birgit Schoeberl, Anthony C Faber, Danan Li, et al.
The Oncologist
|
March 30, 2016
MET Exon 14 Skipping in Non-Small Cell Lung Cancer
Rebecca S Heist, Hyo Sup Shim, Shalini Gingipally, et al.
Nature
|
June 25, 2016
A combinatorial strategy for treating KRAS-mutant lung cancer
Eusebio Manchado, Susann Weissmueller, John P Morris, et al.
Page
of 24
Search research articles
Search
Showing results (131-140 of 238) with videos related to
Sort By:
Page
of 24
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 14, 2012
Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer
A T Shaw, A M Varghese, B J Solomon, et al.
Nature Medicine
|
November 11, 2014
Anchored multiplex PCR for targeted next-generation sequencing
Zongli Zheng, Matthew Liebers, Boryana Zhelyazkova, et al.
Cancer Research
|
March 29, 2014
Failure to induce apoptosis via BCL-2 family proteins underlies lack of efficacy of combined MEK and PI3K inhibitors for KRAS-mutant lung cancers
Aaron N Hata, Alan Yeo, Anthony C Faber, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
August 29, 2016
Programmed Cell Death Ligand 1 Expression in Resected Lung Adenocarcinomas: Association with Immune Microenvironment
Tiffany G Huynh, Vicente Morales-Oyarvide, Meghan J Campo, et al.
Cancer Cell
|
December 30, 2014
Measurement of PIP3 levels reveals an unexpected role for p110β in early adaptive responses to p110α-specific inhibitors in luminal breast cancer
Carlotta Costa, Hiromichi Ebi, Miriam Martini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 1, 2015
Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib
Justin F Gainor, Daniel S W Tan, Tomasso De Pas, et al.
Oncogene
|
August 8, 2017
Synergistic activity and heterogeneous acquired resistance of combined MDM2 and MEK inhibition in KRAS mutant cancers
A N Hata, S Rowley, H L Archibald, et al.
Cancer Research
|
March 11, 2010
An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation
Birgit Schoeberl, Anthony C Faber, Danan Li, et al.
The Oncologist
|
March 30, 2016
MET Exon 14 Skipping in Non-Small Cell Lung Cancer
Rebecca S Heist, Hyo Sup Shim, Shalini Gingipally, et al.
Nature
|
June 25, 2016
A combinatorial strategy for treating KRAS-mutant lung cancer
Eusebio Manchado, Susann Weissmueller, John P Morris, et al.
Page
of 24